Apelin agonism causes systemic vasodilatation and increased cardiac contractility in humans, and improves pulmonary arterial hypertension (PAH) in animal models. Here, the authors examined the short-term pulmonary hemodynamic effects of systemic apelin infusion in patients with PAH. In a double-blind randomized crossover study, 19 patients with PAH received intravenous (Pyr1)apelin-13 and matched saline placebo during invasive right heart catheterization. (Pyr1)apelin-13 infusion caused a reduction in pulmonary vascular resistance and increased cardiac output. This effect was accentuated in the subgroup of patients receiving concomitant phosphodiesterase type 5 inhibition. Apelin agonism is a novel potential therapeutic target for PAH.
|Journal||JACC: Basic to Translational Science|
|Early online date||28 Mar 2018|
|Publication status||Published - Apr 2018|
- Apelin pulmonary hypertension
Brash, L., Peacock, A., Newby, D., & Welsh, D. (2018). Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension. JACC: Basic to Translational Science, 28(2), 176-186. https://doi.org/10.1016/j.jacbts.2018.01.013